Hematology and Oncology Disease

Clinicopathological characteristics of H3 K27-altered diffuse midline gliomas: an analysis of 95 pediatric cases

  • Qi ZHOU ,
  • Jia WANG ,
  • Jinhua LI
Expand
  • 1. Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Department of Pathology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received date: 2022-03-11

  Online published: 2023-03-10

Abstract

Objective To investigate the clinicopathological characteristics of pediatric H3 K27-altered diffuse midline gliomas (DMG). Methods The clinical and pathological data of children first diagnosed with H3 K27-altered DMG from September 2016 to July 2021 were retrospectively analyzed. Results A total of 95 patients (54 boys and 41 girls) were included, and the median age was 6.0 (5.0-9.0) years. Brainstem was the predilection site (82.1%). WHO histological grade 1-4 tumors were found in all cases and high-grade gliomas were found in most cases (65.3%). Immunohistochemical detection showed that H3 K27M (the 27th lysine of histone H3 changed to methionine) was positively expressed in all cases, and H3 K27Me3 (the trimethylation of the 27th lysine of histone H3) was decreased in 89.0% of the children. Mutant p53 (P53) was expressed in 55.6% of the children. The expression rate of isocitrate dehydrogenase 1 (IDH1) and loss expression rate of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) were low (8.5% and 18.6%, respectively). V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) was positive in only 1 case (1.2%). Molecular tests showed that O-6-methylguanine-DNA methyltransferase (MGMT) methylation was detected in 8 cases (47.1%, 8/17), and BRAF variation was detected in 1 case (2.1%, 1/48). Conclusions The commonest location of H3 K27-altered DMG children is the brainstem, and the histological grade is mostly high. ATRX loss in pediatric cases is less common and had no relationship with the tumor location.

Cite this article

Qi ZHOU , Jia WANG , Jinhua LI . Clinicopathological characteristics of H3 K27-altered diffuse midline gliomas: an analysis of 95 pediatric cases[J]. Journal of Clinical Pediatrics, 2023 , 41(3) : 210 -214 . DOI: 10.12372/jcp.2023.22e0347

References

[1] Hawkins C, Ellison DW, Sturm D. Diffuse midline glioma, H3 K27M-mutant[M]// Louis DN, Ohgaki H, Wiestler OD, et al. The 2016 WHO classification of tumors of the central nervous system (4th ed). Lyon: IARC, 2016: 57-59.
[2] WHO Classification of Tumours Editorial Board. The 2021 WHO classification of tumors of the central nervous system (5th ed)[M]. Lyon: IARC, 2021.
[3] 马东林, 姚晶晶, 尹洪芳. 弥漫中线胶质瘤伴H3 K27M突变的研究进展[J]. 中华病理学杂志, 2018, 47(4): 314-317.
[4] Chi AS, Tarapore RS, Hall MD, et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201[J]. J Neurooncol, 2019, 145(1): 97-105.
[5] 曹亚先, 王芮, 陈臻, 等. 儿童弥漫性中线胶质瘤,H3K27M 突变型的MRI 表现[J]. 影像诊断与介入放射学, 2020, 29(5): 343-348.
[6] Ferris SP, Hofmann JW, Solomon DA, et al. Charac-terization of gliomas: from morphology to molecules[J]. Virchows Arch, 2017, 471(2): 257-269.
[7] Huang T, Garcia R, Qi J, et al. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes[J]. Oncotarget, 2018, 9(98): 37112-37124.
[8] Wang L, Li Z, Zhang M, et al. H3 K27M-mutant diffuse midline gliomas in different anatomical locations[J]. Hum Pathol, 2018, 78: 89-96.
[9] Schulte JD, Buerki RA, Lapointe S, et al. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults[J]. Neurooncol Adv, 2020, 2(1): vdaa142.
[10] 李海南, 山常国, 范冲竹, 等. H3K27M突变型弥漫性中线胶质瘤30例临床病理学特征和预后分析[J]. 中华病理学杂志, 2019, 48(3): 192-198.
[11] Castel D, Kergrohen T, Tauziede-Espariat A, et al. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation[J]. Acta Neuropathol, 2020, 139(6): 1109-1113.
[12] Erker C, Lane A, Chaney B, et al. Characteristics of patients≥ 10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG registry[J]. Neuro Oncol, 2022, 24(1): 141-152.
[13] Enomoto T, Aoki M, Hamasaki M, et al. Midline glioma in adults: clinicopathological, genetic, and epigenetic analysis[J]. Neurol Med Chir (Tokyo), 2020, 60(3): 136-146.
[14] Meyronet D, Esteban-Mader M, Bonnet C, et al. Characteristics of H3 K27M-mutant gliomas in adults[J]. Neuro Oncol, 2017, 19(8): 1127-1134.
[15] Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group[J]. Neuro Oncol, 2011, 13(4): 410-416.
[16] Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma[J]. Nat Genet, 2014, 46(5): 444-450.
Outlines

/